LiverGut protocol tests whether microbiome therapy can alter the course of decompensated cirrhosis
Decompensated cirrhosis remains one of hepatology’s most unforgiving clinical states. Once portal hypertension, ascites, encephalopathy, variceal bleeding, or other decompensating events appear, the disease is no longer confined to scarred liver tissue; it becomes a systemic disorder in which gut permeability, bacterial translocation, immune activation, and circulatory dysfunction reinforce one another. The LiverGut trial was designed around that biology. Investigators are testing whether faecal microbiota transplantation can reduce new decompensation events and improve transplant-free survival in patients with decompensated cirrhosis.
The study is a randomised, double-blind, placebo-controlled protocol, a design that matters because microbiome interventions are especially vulnerable to expectation bias and confounding. Patients with advanced liver disease often fluctuate between temporary stability and abrupt clinical deterioration, so an untreated comparison arm is essential if the field wants a credible signal rather than wishful interpretation. The trial is publicly funded, investigator-initiated, and independent, which gives it a different kind of scientific weight: no commercial sponsor is steering the question, the comparator, or the interpretation of response.
Why the gut remains central in advanced liver disease
In cirrhosis, the intestinal ecosystem is not a bystander. Altered microbial diversity, impaired epithelial barrier function, and overgrowth of potentially pathogenic organisms can intensify endotoxin exposure and amplify systemic inflammation. Those processes contribute to worsening portal pressure, infection risk, encephalopathy, and repeated hospitalisation. An intervention such as FMT is attractive because it does not aim to patch a single downstream complication; it tries to reset the microbial environment that helps sustain the broader decompensated state.
The protocol is especially notable for pairing the clinical endpoint with mechanistic sampling. Blood, urine, saliva, and stool will all be collected, allowing investigators to map changes beyond a binary hospital outcome. Portal pressure measurement, immunological profiling, and microbiome analysis are built into the study design. In practical terms, the trial is asking a deeper question than whether patients live longer without transplant. It is asking whether a reshaped microbiome can cool the inflammatory and hemodynamic forces that push cirrhosis toward repeated decompensation.
One sentence captures the biological ambition of the study: the intervention is not only intended to change stool composition, but to alter the host–microbe interaction that drives clinical decline.
Trial design aims to separate signal from noise
Blinding and placebo control are crucial here because FMT is a highly visible intervention with strong procedural expectations. Patients and clinicians can easily attribute improvement to any invasive treatment if the disease has a naturally variable course. A blinded design helps protect the endpoint from enthusiasm bias, especially when outcomes such as decompensation events and transplant-free survival can be influenced by clinical judgment, surveillance intensity, and thresholds for admission.
The FMT material is produced from rigorously screened healthy donors under Good Manufacturing Practice conditions. This is not a casual stool-sharing model; the manufacturing framework is built to support safety, consistency, and reproducibility. The donors are not selected in a personalised manner, which introduces a limitation but also an advantage for the science. A standardised donor strategy reduces one major source of variability and makes it easier to study treatment response across a multicentre cohort. If benefit emerges, the result will be less dependent on a single donor’s microbiome profile and more relevant to real-world implementation.
The study is being conducted across tertiary hospitals in Spain. That nationwide multicentre structure should improve feasibility and reflect routine hepatology care rather than the narrow setting of a single expert center. Real-world applicability matters in decompensated cirrhosis, where patients often have multiple comorbidities, recurrent admissions, and shifting transplant eligibility. A protocol that can be delivered across several hospitals is more likely to inform everyday hepatology practice if the intervention proves useful.
Endpoints tied to clinically meaningful outcomes
The central outcomes are straightforward: new decompensation events and transplant-free survival. Those are the right endpoints for a disease in which symptom control alone is not enough. A patient with cirrhosis may survive an admission, recover from an episode of encephalopathy, or transiently respond to diuretics, yet still face recurrent clinical instability. By anchoring the trial to decompensation and survival without transplant, the investigators are focusing on the outcomes that matter most to patients, families, and transplant teams.
The protocol also reflects a recognition that liver disease cannot be evaluated purely through hepatobiliary labs. Portal pressure, immune activation, and microbiome composition may reveal whether a biological response precedes the clinical one. If FMT modifies these pathways, it could help explain why some patients stabilize while others continue to decline despite standard care. If the mechanistic sampling shows no meaningful shift, the field will learn just as much about the boundaries of microbiome-based therapy in advanced liver disease.
What the protocol can and cannot answer yet
This is a protocol, not a results paper, so no efficacy or safety outcomes are available from the study description itself. The value of the report lies in its structure, scope, and biological intent. It establishes that investigators are testing a plausible but unproven intervention in a population with urgent unmet need, using a design strong enough to support inference if the trial is completed as planned.
The limitations are clear from the outset. Conducting the work in one country may narrow generalisability, especially if patient characteristics, transplant pathways, or supportive care differ elsewhere. The donor strategy is standardised rather than personalised, which simplifies execution but may obscure whether specific donor features influence response. Even so, the existence of similar trials internationally suggests that LiverGut will not stand alone; its findings will join a growing body of global evidence on microbiome-directed therapy in advanced liver disease.
The most consequential question is practical and immediate: can faecal microbiota transplantation interrupt the cycle of intestinal dysbiosis, inflammation, and portal hypertensive deterioration in decompensated cirrhosis? The protocol sets up the right test. The results will determine whether that biological logic translates into fewer decompensations, longer transplant-free survival, and a treatment strategy that hepatologists can actually use at the bedside.